- #142: Die ökonomische und gesellschaftliche Dimension elterlicher psychischer Erkrankungen
- #141: Prozess und Bewertung digitaler Gesundheitsanwendungen am Beispiel der „Symptom-Checker“
- #140: Nivolumab beim malignen Melanom: Kontrastierung der Evidenz aus den Zulassungsstudien mit der Real World Evidenz (RWE)
- #139: Nationale Strategien und Programme zu Prävention und Management nicht-übertragbarer Krankheiten in ausgewählten Ländern
- #138: (Gute) Praxis Organisationsmodelle für die öffentliche Finanzierung von hochpreisigen Therapien unter Verwendung von Anwendungsevidenz
- #137: Evidence-based reimbursement processes in Europe Part 2: A comparative analysis of selected medical devices in Austrian, English. French and German hospitals and possible influencing factors (abgeschlossen/unveröffentlicht)
- #136: Evidenzbasierte Erstattungsprozesse in Europa Teil 1: Erstattungsentscheidungen zu medizinischen Verfahren in Österreich. Eine Analyse von beeinflussenden Faktoren zugunsten/ gegen Erstattungen am Beispiel des österreichischen Spitals-Leistungskatalogs (abgeschlossen/unveröffentlicht)
- #135b: Long-Covid Versorgungspfade: Eine systematische Übersichtsarbeit
- #135a: Epidemiologie von Long-Covid: ein vorläufiger Bericht. Deutsche Kurzfassung zum gleichnamigen KCE-Bericht
- #11: Stuhl-DNA-Test zur Früherkennung von Darmkrebs
- #10: Nicht-Interventionelle Studien (NIS) in Österreich, 2. Update der systematischen Analysen 2016 & 2017
- #9: Bamlanivimab monotherapy and as combination therapy (with etesevimab) for Covid-19
- #8: Kombinationstherapie mit Casirivimab plus Imdevimab (REGN-COV2) bei Covid-19
- #7: Transparenz: Sponsoring von Patienteninitiativen, Update
- #1/1. Update 2021: ≥ 12 Monate Nachbeobachtung von Patient*innen mit spinaler Muskelatrophie (SMA), die mit Spinraza®, Zolgensma® oder Kombinationstherapien behandelt wurden
- DSD 129: Chirurgische Interventionen zur Behandlung der benignen Prostatahyperplasie – Dt. Zusammenfassung des EUnetHTA Assessments
- DSD 128: Allogene Knochenschraube Shark Screw® bei Hallux Valgus
- DSD 127: Endoskopische Antirefluxtherapie bei Patient*innen mit GERD
- DSD 126: Dreiphasiges Biomaterial zur Augmentation des osteoporotischen Oberschenkelhalses
- DSD 125: Liposuktion bei Lipödem
- DSD 124: Perkutane mikro-axiale Flusspumpe (Impella) für die Kreislaufunterstützung
- Update / DSD 87/1. Update: Implantierbare Bulking Agents bei Stuhlinkontinenz
- #71/Update: Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation
- #70/Update: Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC)
- #69/Update: Amivantamab (Rybrevant) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)
- #68/Update: Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the treatment of advanced or recurrent endometrial carcinoma (EC)
- #67/Update: Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC)
- #66: Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer
- #65: Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer
- #64/Update: Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)
- #63/Update: Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2?negative advanced or metastatic gastric, gastro?oesophageal junction or oesophageal adenocarcinoma
- #62/2. Update: Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST)
- #61/2. Update: Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC)
- #60/Update: Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with waldenström’s macroglobulinaemia (WM)
- #59/Update: Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC)
- #58: Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- #57/Update: Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM)
- #56/Update: Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis
- #55/Update: Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM)
- #54/Update: Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapyfor the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus
- #53/Update: Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC)
- #52/Update: Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)
- #51/Update: Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer
- #50/Update: Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma
- #49/Update: Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)
- #48/Update: Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC)
- #47/Update: Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)
- #46/Update: Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)
- #45/Update: Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)
- #44/Update: Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL)
- #43/Update: Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)
- #42/Update: Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
- #41/2. Update: Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)
- #40/Update: Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
- #39/2. Update: Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)
- #38/Update: Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)